KAREN G ANTHONY

Summary

Publications

  1. ncbi Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus
    Michel Ledizet
    L2 Diagnostics, Department of Internal Medicine, Yale School of Medicine, 300 George Street, New Haven, CT 06525, USA
    J Infect Dis 196:1741-8. 2007
  2. ncbi Effective siRNA targeting of the 3' untranslated region of the West Nile virus genome
    KAREN G ANTHONY
    L2 Diagnostics, LLC, New Haven, CT, United States
    Antiviral Res 82:166-8. 2009
  3. ncbi New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis
    KAREN G ANTHONY
    L2 Diagnostics, LLC, New Haven, Connecticut, United States of America
    PLoS ONE 6:e20374. 2011
  4. ncbi Thiadiazolidinones: a new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureus
    Mihai Ciustea
    L2 Diagnostics, LLC, 300 George St, New Haven, CT 06511, USA
    Biochem Pharmacol 83:368-77. 2012
  5. ncbi A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF)
    Fengwei Bai
    L2 Diagnostics, LLC, New Haven, CT 06511, USA
    J Biol Chem 287:30653-63. 2012

Research Grants

  1. Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis
    Karen Anthony; Fiscal Year: 2006

Collaborators

  • Michel Ledizet
  • Nathalie Bonafe
  • Mihai Ciustea
  • Fengwei Bai
  • Raymond A Koski
  • Paul A Aristoff
  • Pier Cirillo
  • Paul A Kaplan
  • Oriana Perez
  • Sara Mootien
  • Adriana E Rosato
  • Lin Leng
  • Kacheong R Yeung
  • Michael H Cynamon
  • Richard Bucala
  • THOMAS J POWELL
  • Oluwatoyin A Asojo

Detail Information

Publications5

  1. ncbi Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus
    Michel Ledizet
    L2 Diagnostics, Department of Internal Medicine, Yale School of Medicine, 300 George Street, New Haven, CT 06525, USA
    J Infect Dis 196:1741-8. 2007
    ..These immunoglobulins recognized the E proteins of related flaviviruses, demonstrating that antibodies targeting specific E protein epitopes could be developed for prevention and treatment of multiple flavivirus infections...
  2. ncbi Effective siRNA targeting of the 3' untranslated region of the West Nile virus genome
    KAREN G ANTHONY
    L2 Diagnostics, LLC, New Haven, CT, United States
    Antiviral Res 82:166-8. 2009
    ..The siRNAs developed in this study could function as potential antiviral therapeutics and as genetic tools to investigate the role of 3' UTR in WNV pathogenesis...
  3. ncbi New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis
    KAREN G ANTHONY
    L2 Diagnostics, LLC, New Haven, Connecticut, United States of America
    PLoS ONE 6:e20374. 2011
    ..Therefore, inhibitors that are not substrate analogs and that act through different mechanisms of enzyme inhibition are necessary for therapeutic development for this drug target...
  4. ncbi Thiadiazolidinones: a new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureus
    Mihai Ciustea
    L2 Diagnostics, LLC, 300 George St, New Haven, CT 06511, USA
    Biochem Pharmacol 83:368-77. 2012
    ..Lead development centering on the thiadiazolidinone series would require additional medicinal chemistry efforts to enhance the antibacterial activity and minimize mammalian cell toxicity...
  5. ncbi A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF)
    Fengwei Bai
    L2 Diagnostics, LLC, New Haven, CT 06511, USA
    J Biol Chem 287:30653-63. 2012
    ..The mode of p425 binding reveals a unique way to block the activity of the cytokine for potential therapeutic benefit in MIF-associated diseases...

Research Grants2

  1. Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis
    Karen Anthony; Fiscal Year: 2006
    ..About 50 million people are infected with TB bacteria that are not susceptible to available antibiotics. The goal of this research is to develop new antibiotics to treat drug-resistant TB. ..